Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567057 | 0.88 | CYP2D6 (0.39) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL14530947 | 0.78 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL23866552 | 0.78 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL21451659 | 0.76 | KDM4E (0.34) | SMN1; SMN2TSHR | |
| SCHEMBL23560004 | 0.75 | CYP2D6 (0.58) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL18926689 | 0.75 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL11972009 | 0.75 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL20007909 | 0.74 | CYP2D6 (0.42) | CYP2D6ALDH1A1 | |
| SCHEMBL8881442 | 0.73 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL3422699 | 0.73 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | CUMBRE INC. (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | RIF1, MAPRE1, MAPRE2 | CYP2D6 688/4885SMN1; SMN2 4541/4885PIK3CD 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.